Pharmaron Beijing stock

300759 · SZSE · CNY

Compare Pharmaron Beijing
¥39.29Change from previous close: −3.94%Absolute change: −¥1.61

Close · November 18, 2026

Price history

+33.10% over the period

1 year: from ¥29.52 (November 18, 2025) to ¥39.29 (November 18, 2026), +33.10%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 18, 2026¥39.29
October 30, 2026¥41.37
September 30, 2026¥44.97
August 31, 2026¥43.30
July 31, 2026¥36.80
June 30, 2026¥28.93
May 29, 2026¥25.10
April 30, 2026¥29.31
March 31, 2026¥27.98
February 27, 2026¥29.60
January 30, 2026¥29.68
December 31, 2025¥28.43
November 28, 2025¥28.95
November 18, 2025¥29.52

At a glance

  • The company

    Provides pharmaceutical research and development services including drug discovery, chemical manufacturing, clinical research and cell and gene therapy

  • Latest results

    Quarter to September 30, 2026 · EPS ¥0.27 (estimate ¥0.30)

TickerLandia's take on Pharmaron Beijing

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥21.01
52-wk high¥53.57

−26.66% from the 52-week high

Analysts · 13 analysts

Average target¥50.40+28.29% vs. price

Buy 9 · Hold 3 · Sell 1 · Buy

TickerLandia Fingerprint: Pharmaron Beijing

Compared with similar companies: very high earnings stability and very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Pharmaron Beijing is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Pharmaron Beijing's P/E today is 41.8, below the median of its last 7 fiscal years (58.6; between 25.4 and 81.5 from 2019 to 2025). Pharmaron Beijing's P/E (trailing 12 months): 42.4, +7% against the median of a group of 8 similar companies (39.6).

P/E compared with its history

Compared with 8 similar companies

Pharmaron Beijing's metrics compared with similar companies
MetricPharmaron BeijingPosition in the groupBand
P/E (trailing 12 months)42.4Middle
Forward P/E28.0Middle
Operating margin14.0%Middle
ROE10.4%Middle
Debt/equity0.42High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pharmaron Beijing. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥4.41B

Latest quarter · Q3 2026

Net income

¥496.93M

Latest quarter · Q3 2026

Quarterly net margin

11.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥76.36B
P/E
42.4
EPS
¥0.98
Volume
15.32M
Daily trading
€245.3M
Dividend yield
0.51%
Last ex-dividend on July 7, 2026

How Pharmaron Beijing is changing

All results
  • Revenue grew 22.4% a year on average over the last 5 years

  • Operating margin fell from 16.2% to 14.5%

  • Less cash than profit: free cash flow equal to 19% of net income

Returns

Pharmaron Beijing returns with dividends

¥1,000 invested in Pharmaron Beijing 5 years ago, on November 18, 2021, would be worth ¥499 today with dividends reinvested: −50.14% in total, −13.00% per year. On price alone it would be ¥478 (−52.21%).

PeriodPharmaron Beijing¥1,000 becomes
1 month+2.05%¥1,021
6 months+49.16%¥1,492
Year to date+38.20%¥1,382
1 year+33.97%¥1,340
3 years+17.40%¥1,174
5 years−50.14%¥499

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Pharmaron Beijing: technical analysis

Pharmaron Beijing shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 62.2% below its all-time closing high (¥103.85, August 5, 2021).

Trend
No clear trend
RSI (14 sessions)
42
Between 30 and 70
vs 200-session average
+15.28%

Active signals

  • The last session opened more than 3% above the previous close.

    since November 17, 2026

Support and resistance

Price areas where Pharmaron Beijing has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance¥46.62+18.64%2 touches, last on October 8, 2026
  2. Last price¥39.29
  3. Support¥34.96−11.03%3 touches, last on October 19, 2026
  4. Support¥31.67−19.40%3 touches, last on April 28, 2026
  5. Support¥29.06−26.04%8 touches, last on March 12, 2026

Volatility and risk

Volatility (60 sessions, annualised)
60.9%
Largest fall in the last year
−34.00%

In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Pharmaron Beijing: seasonality

Average monthly price change over 8 years

−0.1%Jan+18.9%Feb−1.0%Mar−0.6%Apr+0.4%May+8.4%Jun+8.4%Jul+2.3%Aug+9.4%Sep+0.7%Oct−4.9%Nov−0.2%Dec

Over the last 8 years, the strongest month for Pharmaron Beijing has been February: +18.93% on average, positive in 4 years out of 8. The weakest has been November: −4.86% on average, positive in 2 years out of 7.

Show chart data
MonthAverageMedianPositive years
January−0.06%+4.40%4 of 7
February+18.93%+1.13%4 of 8
March−0.99%−0.42%4 of 8
April−0.60%+2.37%4 of 8
May+0.38%+1.20%4 of 8
June+8.40%+9.10%5 of 8
July+8.39%+8.76%6 of 8
August+2.26%+1.08%4 of 8
September+9.36%+7.89%6 of 8
October+0.72%−3.84%3 of 8
November−4.86%−5.69%2 of 7
December−0.22%−1.80%3 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Pharmaron Beijing and its competitors

Laboratory Services, the first of the five segments through which Pharmaron Beijing Co., Ltd. and its subsidiaries operate, provides chemistry and biological science services for small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates and cell and gene therapy products. The company also runs small molecule CDMO services, covering API process development and production, formulation and analytical development, alongside clinical research and macromolecular and cell and gene therapy services that span drug discovery through to production.

Headquarters
Beijing, China
Employees
25,088
Founded
2004
Chief executive
Boliang Lou
Pharmaron Beijing and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Pharmaron Beijing300759$11.45B14.0%42.4+49.16%
Sino Biopharmaceutical1177$12.49B28.2%36.7+0.57%
Haisco Pharmaceutical Group002653$9.79B21.1%50.6+4.89%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—−1.27%
ALTEOGEN196170$9.17B47.2%97.1−38.65%
Genscript Biotech1548$8.83B14.9%—+111.76%

Same industry or related industries, similar size. Compare Pharmaron Beijing with its competitors · Full profile